Medicines for Europe is the new name of EGA as of today. Representing the pharmaceutical companies supplying the largest share of medicines across Europe, Medicines for Europe is the voice of the generic, biosimilar and value added medicines industries in Europe and a leading partner providing better health and better access to all European patients.
The European Generic and Biosimilar Medicines Association is now Medicines for Europe Better access. Better health. Generic medicines are now the cornerstone of European healthcare, the Biosimilar medicines sector is developing rapidly, and the need and opportunity for Value Added medicines will further transform healthcare. Our industries supply the majority of Europe’s prescription medicines which is estimated to grow from the current 56% to 75% in volume over the next 5 years, as the demand for access to high quality medicines for European patients has never been greater. The repositioning of our association as Medicines for Europe aims to drive greater healthcare efficiency through better health outcomes while providing solutions for the sustainability of European healthcare systems facing increased demographic demands on healthcare services.
“Medicines for Europe Better access. Better health reflects our industries’ purpose and strategic objectives,” said Medicines for Europe President Jacek Glinka. “As an organisation we have been through an incredible journey responding to the changes that have taken place in the pharmaceutical industry and European healthcare environment. I invite stakeholders and policy-makers to engage with us to deliver access to high quality medicines for all European patients.”
Adrian van den Hoven, Medicines for Europe Director General, added: “Medicines for Europe is a great opportunity to build on the EGA’s established reputation for partnership with stakeholders and authorities to deliver access to high quality medicines for patients, its commitment to the highest levels of quality, and to bringing even more value to pharmaceuticals while bridging the sustainability of healthcare with a competitive pharmaceutical manufacturing industry.”